[by Lee, Young Sung] Dong-A ST announced on August 19 that it has launched ‘IMULDOSA (project name DMB-3115, ustekinumab),’ a biosimilar to ‘STELARA,’ in the U.S. market through its global partners, the multinational pharmaceutical companies Intas Pharmaceuticals and Accord BioPharma.
강원 랜드 바카라 is a biosimilar to Janssen’s original drug ‘STELARA,’ prescribed for inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
STELARA has generated global sales of approximately USD 21.552 billion (based on 2024 estimates, according to IQVIA).
강원 랜드 바카라 has already rolled out in 14 countries, including Germany, the United Kingdom, and Spain, and has also secured marketing approval in the MENA region, covering markets such as Saudi Arabia, Qatar, and the United Arab Emirates.
"With 강원 랜드 바카라’s U.S. debut following its launch in Europe, our global expansion is gaining momentum. We are committed to ensuring that 강원 랜드 바카라 becomes a trusted treatment option for patients worldwide," a Dong-A ST official said.
강원 랜드 바카라 has been co-developed by Dong-A Socio Holdings and Meiji Seika Pharma since 2013. In July 2020, the development and commercialization rights were transferred to Dong-A ST to streamline global project execution, after which Dong-A ST and Meiji Seika Pharma continued their co-development efforts.
In July 2021, Dong-A ST entered into a global licensing agreement for 강원 랜드 바카라 with multinational pharmaceutical company Intas Pharmaceuticals. Under the deal, Intas is commercializing 강원 랜드 바카라 through its affiliates, including Accord Biopharma in the U.S. and Accord Healthcare in Europe, the U.K., and Canada.